Table 2.
Presence of a mutation versus metastasis-free survival (MFS) and recurrence-free survival (RFS).
| Gene | Presence of a Mutation | n (%) | Metastasis n (%) | MFS p-Value |
Recurrences n (%) | RFS p-Value |
|---|---|---|---|---|---|---|
| SF3B1 | 0.45 | 0.45 | ||||
| Yes | 1 (4) | 0 (0) | 0 (0) | |||
| No | 27 (96) | 9 (33) | 8 (30) | |||
| BAP1 | 0.46 | 0.69 | ||||
| Yes | 5 (18) | 1 (20) | 2 (40) | |||
| No | 23 (82) | 8 (35) | 6 (26) | |||
| TERT | 0.008 | 0.20 | ||||
| Yes | 15 (54) | 7 (47) | 2 (13) | |||
| No | 13 (46) | 2 (15) | 6 (46) | |||
| NRAS | 0.17 | 0.82 | ||||
| Yes | 6 (21) | 4 (67) | 2 (33) | |||
| No | 22 (79) | 5 (23) | 6 (27) | |||
| KIT | 0.26 | 0.88 | ||||
| Yes | 2 (7) | 0 (0) | 1 (50) | |||
| No | 26 (93) | 9 (35) | 7 (28) | |||
| PTEN | 0.53 | 0.25 | ||||
| Yes | 4 (14) | 1 (25) | 2 (50) | |||
| No | 24 (86) | 8 (33) | 6 (25) | |||
| BRAF | 0.052 | 0.76 | ||||
| Yes | 13 (46) | 5 (38) | 2 (15) | |||
| No | 15 (54) | 4 (27) | 6 (40) |
The total number of included conjunctival melanoma cases was twenty-eight. This table depicts the percentages of the specific mutations in the cohort, as well as the development of metastatic disease and recurrent disease within the group of a specific mutation. The statistically significant p-value is depicted in bold. MFS = metastasis-free survival. RFS = recurrence-free survival.